Patents by Inventor Emma E. Moore
Emma E. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8084426Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.Type: GrantFiled: May 20, 2010Date of Patent: December 27, 2011Assignee: ZymoGenetics, Inc.Inventors: Emma E. Moore, Jeff L. Ellsworth
-
Publication number: 20100291212Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.Type: ApplicationFiled: May 20, 2010Publication date: November 18, 2010Applicant: ZYMOGENETICS, INC.Inventors: Emma E. Moore, Jeff L. Ellsworth
-
Patent number: 7749965Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.Type: GrantFiled: April 15, 2008Date of Patent: July 6, 2010Assignee: ZymoGenetics, Inc.Inventors: Emma E. Moore, Jeff L. Ellsworth
-
Publication number: 20090285775Abstract: IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in order to accelerate the wound healing process. The present invention further encompasses a pharmaceutical composition and formulations thereof that utilize IL-17B, either alone or in combination with other cytokines or growth factors known to aid wound healing. The invention also contemplates methods of treating wounds in patients using this pharmaceutical composition.Type: ApplicationFiled: June 15, 2009Publication date: November 19, 2009Inventors: Emma E. Moore, Harald S. Haugen
-
Publication number: 20080193501Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.Type: ApplicationFiled: April 15, 2008Publication date: August 14, 2008Inventors: Emma E. Moore, Jeff L. Ellsworth
-
Publication number: 20080159979Abstract: IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in order to accelerate the wound healing process. The present invention further encompasses a pharmaceutical composition and formulations thereof that utilize IL-17B, either alone or in combination with other cytokines or growth factors known to aid wound healing. The invention also contemplates methods of treating wounds in patients using this pharmaceutical composition.Type: ApplicationFiled: November 7, 2006Publication date: July 3, 2008Inventors: Emma E. Moore, Harald S. Haugen
-
Publication number: 20040234500Abstract: The present invention relates to a method for promoting the proliferation of retinal stem cells using IL-17B. IL-17B is put into a cell culture medium containing retinal stem cells to promote the proliferation and/or differentiation of retinal stem cells. The retinal stem cells can then be transplanted into the retina to promote the growth of the photoreceptor cells, the rods and the cones. Also IL-17B can be administered directly into the retina to promote the proliferation and/or differentiation of the retinal stem cells.Type: ApplicationFiled: May 3, 2004Publication date: November 25, 2004Inventors: Emma E. Moore, Thomas Reh
-
Publication number: 20040115191Abstract: A method for treating psoriasis. An antagonist to IL-17D&bgr;9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17D&bgr;9 or its receptor or a soluble receptor that binds to IL-17D&bgr;9 or a membrane-spanning protein-5 (MSP-5).Type: ApplicationFiled: January 29, 2004Publication date: June 17, 2004Inventors: Emma E Moore, Kevin P Foley, Karen L Madden, Yue Yao, Scott R Presnell
-
Patent number: 6569419Abstract: A method for promoting the expression of myelin or Protein Zero in Schwann cells using Zcyto7 or IL-17. Zcyto7 or IL-17 are further used to promote myelination of the peripheral nervous system. This is particularly useful in treating diseases dymyelinating diseases such as diabetic neuropathy, Guillain-Barré Syndrome, chronic demyelinating disease, acute demyelinating polyneuropathy and human immunodeficiency viral demyelinating neuropathy or demyelination caused by trauma.Type: GrantFiled: February 27, 2001Date of Patent: May 27, 2003Assignee: ZymoGenetics, Inc.Inventors: Emma E. Moore, Julia E. Novak
-
Publication number: 20020077467Abstract: Novel mammalian calcitonin-like polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.Type: ApplicationFiled: May 1, 2001Publication date: June 20, 2002Applicant: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Emma E. Moore, Fenella Raymond
-
Patent number: 6395740Abstract: Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.Type: GrantFiled: July 14, 2000Date of Patent: May 28, 2002Assignee: ZymoGenetics, Inc.Inventors: Nand Baindur, Virender Labroo, Steven Stroop, Stephanie Beigel, Theresa Martinez, Charles R. Petrie, Mark W. Orme, Patricia A. Mckernan, Emma E. Moore
-
Patent number: 6391917Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.Type: GrantFiled: April 19, 2001Date of Patent: May 21, 2002Assignee: ZymoGenetics, Inc.Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
-
Publication number: 20020039568Abstract: A method for promoting the expression of myelin or Protein Zero in Schwann cells using Zcyto7 or IL-17. Zcyto7 or IL-17 are further used to promote myelination of the peripheral nervous system. This is particularly useful in treating diseases dymyelinating diseases such as diabetic neuropathy, Guillain - Barré Syndrome, chronic demyelinating disease, acute demyelinating polyneuropathy and human immunodeficiency viral demyelinating neuropathy or demyelination caused by trauma.Type: ApplicationFiled: February 27, 2001Publication date: April 4, 2002Inventors: Emma E. Moore, Julia E. Novak
-
Patent number: 6255351Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.Type: GrantFiled: September 30, 1999Date of Patent: July 3, 2001Assignee: ZymoGenetics, Inc.Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
-
Patent number: 6221913Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.Type: GrantFiled: January 20, 1999Date of Patent: April 24, 2001Assignee: ZymoGenetics, Inc.Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
-
Patent number: 6124299Abstract: Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.Type: GrantFiled: February 23, 1998Date of Patent: September 26, 2000Assignee: ZymoGenetics, Inc.Inventors: Nand Baindur, Virender Labroo, Steven Stroop, Stephanie Beigel, Theresa Martinez, Charles R. Petrie, Mark W. Orme, Patricia A. McKernan, Emma E. Moore
-
Patent number: 5830682Abstract: All lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes, dendritic cells, hepatocytes, myocytes and prostatic cells. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.Type: GrantFiled: December 13, 1996Date of Patent: November 3, 1998Assignee: ZymoGeneticsInventor: Emma E. Moore
-
Patent number: 5683906Abstract: Cell lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes and hepatocytes. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.Type: GrantFiled: September 9, 1994Date of Patent: November 4, 1997Assignee: ZymoGenetics, Inc.Inventor: Emma E. Moore
-
Patent number: 5683884Abstract: Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.Type: GrantFiled: May 30, 1995Date of Patent: November 4, 1997Assignee: ZymoGenetics, Inc.Inventors: Emma E. Moore, Paul O. Sheppard, Rolf E. Kuestner
-
Patent number: 5674689Abstract: Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.Type: GrantFiled: May 30, 1995Date of Patent: October 7, 1997Assignee: ZymoGenetics, Inc.Inventors: Emma E. Moore, Paul O. Sheppard, Rolf E. Kuestner